JPWO2020163823A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020163823A5 JPWO2020163823A5 JP2021546264A JP2021546264A JPWO2020163823A5 JP WO2020163823 A5 JPWO2020163823 A5 JP WO2020163823A5 JP 2021546264 A JP2021546264 A JP 2021546264A JP 2021546264 A JP2021546264 A JP 2021546264A JP WO2020163823 A5 JPWO2020163823 A5 JP WO2020163823A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- compound
- pharmaceutically acceptable
- pharmaceutical composition
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962803299P | 2019-02-08 | 2019-02-08 | |
| US62/803,299 | 2019-02-08 | ||
| PCT/US2020/017364 WO2020163823A2 (en) | 2019-02-08 | 2020-02-07 | Therapeutic agents and methods of treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022520061A JP2022520061A (ja) | 2022-03-28 |
| JPWO2020163823A5 true JPWO2020163823A5 (US07794700-20100914-C00152.png) | 2023-05-23 |
Family
ID=71948254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546264A Pending JP2022520061A (ja) | 2019-02-08 | 2020-02-07 | 治療薬および治療方法 |
Country Status (8)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230330237A1 (en) * | 2020-08-28 | 2023-10-19 | University Of Florida Research Foundation, Incorporated | Modulators of nuclear receptor subfamily 4 group a member 1 (nr4a1) and uses thereof |
| IL304891A (en) | 2021-02-02 | 2023-10-01 | Servier Lab | Selective Protech BCL-XL compounds and methods of use |
| CA3231175A1 (en) | 2021-09-01 | 2023-03-09 | Xizang Haisco Pharmaceutical Co., Ltd. | Compound for degradation of bcl-2 family proteins and medical application thereof |
| WO2023064326A1 (en) * | 2021-10-12 | 2023-04-20 | University Of Florida Research Foundation, Incorporated | Methods of treating diseases associated with senescent cell accumulation |
| CN118660886A (zh) | 2021-12-09 | 2024-09-17 | 佛罗里达大学研究基金公司 | 用于治疗癌症的bcl-xl/bcl-2双重降解剂 |
| CN116396288A (zh) * | 2022-01-04 | 2023-07-07 | 上海科技大学 | 基于bcl-2家族蛋白配体化合物开发的蛋白降解剂及它们的应用 |
| WO2023215449A1 (en) | 2022-05-06 | 2023-11-09 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
| US20240238423A9 (en) | 2022-05-06 | 2024-07-18 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
| WO2023215471A1 (en) | 2022-05-06 | 2023-11-09 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
| CN115028679B (zh) * | 2022-08-11 | 2022-11-15 | 深圳湾实验室 | 一种具有Cyclophilin A降解活性的PROTAC化合物及其制备方法与应用 |
| WO2024077023A2 (en) * | 2022-10-03 | 2024-04-11 | University Of Florida Research Foundation, Incorporated | Cereblon-recruiting bcl-xl/bcl-2 dual degraders |
| WO2024078581A1 (en) * | 2022-10-12 | 2024-04-18 | Appicine Therapeutics (Hk) Limited | Selective bcl-xl protac compounds and uses thereof |
| WO2024153185A1 (zh) * | 2023-01-18 | 2024-07-25 | 苏州宜联生物医药有限公司 | 包含bcl-2家族蛋白降解剂的抗体药物偶联物及其制备方法和用途 |
| WO2024169976A1 (zh) * | 2023-02-17 | 2024-08-22 | 正大天晴药业集团股份有限公司 | 含有三氟甲磺酰基的化合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2979070A1 (en) * | 2015-03-18 | 2016-09-22 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| WO2017024317A2 (en) * | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| CN109152933B (zh) * | 2016-04-21 | 2022-12-02 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
| WO2017197055A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| AU2017370694A1 (en) * | 2016-12-08 | 2019-07-25 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating CDK4/6-mediated cancer |
-
2020
- 2020-02-07 WO PCT/US2020/017364 patent/WO2020163823A2/en unknown
- 2020-02-07 KR KR1020217028572A patent/KR20210137025A/ko unknown
- 2020-02-07 AU AU2020218367A patent/AU2020218367A1/en active Pending
- 2020-02-07 US US17/429,207 patent/US20220169628A1/en active Pending
- 2020-02-07 CA CA3127501A patent/CA3127501A1/en active Pending
- 2020-02-07 EP EP20753239.1A patent/EP3920923A4/en active Pending
- 2020-02-07 JP JP2021546264A patent/JP2022520061A/ja active Pending
- 2020-02-07 CN CN202080027337.5A patent/CN113660937A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4470321B2 (ja) | 抗腫瘍剤 | |
| JPWO2020163823A5 (US07794700-20100914-C00152.png) | ||
| JP2013231086A (ja) | 化学療法の強化方法 | |
| JP2007534730A (ja) | 少なくとも一つのピロロベンゾジアゼピン誘導体とフルダラビンとを含有する治療用組成物 | |
| JP2006523216A5 (US07794700-20100914-C00152.png) | ||
| JP2005533748A5 (US07794700-20100914-C00152.png) | ||
| WO2010031265A1 (zh) | 用于治疗增生性疾病的药物组合物 | |
| JP2008527039A5 (US07794700-20100914-C00152.png) | ||
| JP2005508857A5 (US07794700-20100914-C00152.png) | ||
| US20150005354A1 (en) | Combination Therapy With Parp Inhibitors | |
| MXPA06000191A (es) | Combinacion de los inhibidores de src cinasa y agentes quimioterapeuticos para el tratamiento de enfermedades proliferativas. | |
| CN111902147A (zh) | 五氮杂大环状环配合物和基于铂的抗癌剂的组合癌症治疗 | |
| JP2009536956A (ja) | 抗癌治療法 | |
| US6355628B1 (en) | Combination therapy using pentafluorobenzenesulfonamides | |
| BR112020022654A2 (pt) | Composições de combinação que compreendem compostos de bisfluoroalquil-1,4-benzodiazepinona e métodos de uso das mesmas | |
| EA006295B1 (ru) | Применение производных дистамицина для противоопухолевой терапии | |
| JPWO2021187548A5 (US07794700-20100914-C00152.png) | ||
| JP2006504721A (ja) | 治療剤に対する乳癌耐性タンパク質（ｂｃｒｐ）−介在耐性を阻害するためのイマチニブ（グリベック、ｓｔｉ−５７１）の使用 | |
| JP2002326936A (ja) | 腫瘍転移および癌の治療における５−フルオロウラシルの有効性の増強 | |
| US20020177548A1 (en) | Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents | |
| ES2317913T3 (es) | Tratamiento antitumoral combinado que comprende un derivado de la distamicina sustituida por acriloilo y un antimetabolito. | |
| JP2003535874A5 (US07794700-20100914-C00152.png) | ||
| RU2314807C2 (ru) | Комбинированная противоопухолевая терапия, включающая использование замещенных акрилоилпроизводных дистамицина и лучевой терапии | |
| JP5409613B2 (ja) | 抗腫瘍剤、キット及び癌治療方法 | |
| JP2011514356A5 (US07794700-20100914-C00152.png) |
